Yau T, et al. Checkmate 459: a randomized, multi-center phase 3 study of nivolumab (nivo) vs sorafenib (sor) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (AHCC). Abstract LBA38_PR. ESMO Congress 2019, 28 sept. Barcelona, Spanje.
Antistoffen tegen pariëtale cellen geassocieerd met verhoogd risico op maagkanker
mrt 2022 | Maag-darm-leveroncologie